Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan 1;10(1):5-13.
doi: 10.1586/17446651.2015.971755.

PTH(1-84) replacement therapy for the treatment of hypoparathyroidism

Natalie E Cusano  1 , Mishaela R Rubin  1 , John P Bilezikian  1
Affiliations

PTH(1-84) replacement therapy for the treatment of hypoparathyroidism

Natalie E Cusano et al. Expert Rev Endocrinol Metab. .

Abstract

Hypoparathyroidism is a rare disease characterized by hypocalcemia and insufficient circulating levels of parathyroid hormone (PTH). Conventional therapy includes calcium and active vitamin D supplementation, often in large doses. Therapy with calcium and vitamin D, however, does not address certain problematic aspects of the disease, including abnormal bone metabolism and reduced quality of life. Hypoparathyroidism is the only classic endocrine deficiency disease for which the missing hormone, PTH, is not yet an approved treatment. PTH(1-84) may soon become a therapeutic option for patients with hypoparathyroidism. PTH (1-84) has been demonstrated to maintain serum calcium while reducing or eliminating requirements for calcium and active vitamin D supplementation. Data from bone densitometry, bone turnover markers and histomorphometry of bone biopsy specimens show positive structural and dynamic effects on the skeleton. PTH replacement therapy may also be associated with improved quality of life. PTH(1-84) replacement therapy for hypoparathyroidism is promising, although further acquisition of long-term data is needed.

Keywords: PTH(1-84); hypoparathyroidism; natpara; parathyroid; parathyroid hormone.

PubMed Disclaimer

References

    1. Bilezikian JP, Khan A, Potts JT, Jr, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011;26:2317–37. The proceedings from the First International Workshop on Hypoparathyroidism provide an extensive review on the topic, including epidemiology, diagnosis, pathophysiology and target-organ involvement. - PMC - PubMed
    1. Cusano NE, Rubin MR, Sliney J, Jr, Bilezikian JP. Mini-review: new therapeutic options in hypoparathyroidism. Endocrine. 2012;41:410–14. - PMC - PubMed
    1. Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med. 2008;359:391–403. - PubMed
    1. Mitchell DM, Regan S, Cooley MR, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012;97:4507–14. - PMC - PubMed
    1. Powers J, Joy K, Ruscio A, Lagast H. Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J Bone Miner Res. 2013;28:2570–6. - PubMed